<?xml version="1.0" encoding="utf-8"?>
<journal>
<title>Iranian journal of Pediatric Hematology and Oncology</title>
<title_fa>Iranian journal of Pediatric Hematology and Oncology</title_fa>
<short_title>Iran J Ped Hematol Oncol</short_title>
<subject>Medical Sciences</subject>
<web_url>http://ijpho.ssu.ac.ir</web_url>
<journal_hbi_system_id>1</journal_hbi_system_id>
<journal_hbi_system_user>admin</journal_hbi_system_user>
<journal_id_issn>2008-8892</journal_id_issn>
<journal_id_issn_online>2228-6993</journal_id_issn_online>
<journal_id_pii>8</journal_id_pii>
<journal_id_doi>7</journal_id_doi>
<journal_id_iranmedex></journal_id_iranmedex>
<journal_id_magiran></journal_id_magiran>
<journal_id_sid>14</journal_id_sid>
<journal_id_nlai>8888</journal_id_nlai>
<journal_id_science>13</journal_id_science>
<language>en</language>
<pubdate>
	<type>jalali</type>
	<year>1393</year>
	<month>12</month>
	<day>1</day>
</pubdate>
<pubdate>
	<type>gregorian</type>
	<year>2015</year>
	<month>3</month>
	<day>1</day>
</pubdate>
<volume>5</volume>
<number>1</number>
<publish_type>online</publish_type>
<publish_edition>1</publish_edition>
<article_type>fulltext</article_type>
<articleset>
	<article>


	<language>en</language>
	<article_id_doi></article_id_doi>
	<title_fa></title_fa>
	<title>Low Frequency of C-MPL Gene Mutations in Iranian Patients with Philadelphia-Negative Myeloproliferative Disorders</title>
	<subject_fa>قلب</subject_fa>
	<subject>Heart</subject>
	<content_type_fa>پژوهشي</content_type_fa>
	<content_type>Research</content_type>
	<abstract_fa></abstract_fa>
	<abstract>Background
Myeloproliferative disorders are a group of diseases characterized by increased proliferation of myeloid lineage. In addition to JAK2V617F mutation, several mutations in the c-MPL gene were described in patients with Philadelphia-negative chronic myeloproliferative disorders that could be important in the pathogenesis of diseases.  The aim of present study was to investigate the frequency of c-MPL and JAK2V617F mutations in Iranian patients with Philadelphia-negative myeloproliferative disorders.   
Material and Methods
Peripheral blood samples from 60 patients with Philadelphia-negative MPD) subgroups ET and PMF) and 25 healthy subjects as control were collected in order to investigate the mutation status of c-MPL and Jak2V617F by using Amplification-Refractory Mutation System 

(ARMS) and Allele-Specific PCR (AS-PCR), respectively and results were confirmed by sequencing.  
Results
Among the total 60 patients studied, 34 (56.6%) and 1(1.7%)   had Jak2V617F and c-MPL mutation, respectively. Patients with Jak2V617F mutation had higher WBC counts and hemoglobin concentration than those without the mutation (p= 0.005, p=0.003). In addition for all healthy subjects in control group, mutation was negative.
Conclusions
The present study revealed that the c-MPL mutations unlike the Jak2V617F mutations were rare in Iranian patients with Ph-negative MPNs and the low mutation rate should be considered in the design of screening strategies of MPD patients. 
</abstract>
	<keyword_fa></keyword_fa>
	<keyword>ARMS –PCR, c- MPL mutation, JAK2V617F, Myeloproliferative Disorders</keyword>
	<start_page>43</start_page>
	<end_page>51</end_page>
	<web_url>http://ijpho.ssu.ac.ir/browse.php?a_code=A-10-70-37&amp;slc_lang=en&amp;sid=1</web_url>


<author_list>
	<author>
	<first_name>A</first_name>
	<middle_name></middle_name>
	<last_name>Ghotaslou</last_name>
	<suffix></suffix>
	<first_name_fa></first_name_fa>
	<middle_name_fa></middle_name_fa>
	<last_name_fa></last_name_fa>
	<suffix_fa></suffix_fa>
	<email></email>
	<code></code>
	<orcid></orcid>
	<coreauthor>No</coreauthor>
	<affiliation></affiliation>
	<affiliation_fa></affiliation_fa>
	 </author>


	<author>
	<first_name>F</first_name>
	<middle_name></middle_name>
	<last_name>Nadali</last_name>
	<suffix></suffix>
	<first_name_fa></first_name_fa>
	<middle_name_fa></middle_name_fa>
	<last_name_fa></last_name_fa>
	<suffix_fa></suffix_fa>
	<email></email>
	<code></code>
	<orcid></orcid>
	<coreauthor>No</coreauthor>
	<affiliation></affiliation>
	<affiliation_fa></affiliation_fa>
	 </author>


	<author>
	<first_name>A</first_name>
	<middle_name></middle_name>
	<last_name>Ghasemi</last_name>
	<suffix></suffix>
	<first_name_fa></first_name_fa>
	<middle_name_fa></middle_name_fa>
	<last_name_fa></last_name_fa>
	<suffix_fa></suffix_fa>
	<email></email>
	<code></code>
	<orcid></orcid>
	<coreauthor>No</coreauthor>
	<affiliation></affiliation>
	<affiliation_fa></affiliation_fa>
	 </author>


	<author>
	<first_name>B</first_name>
	<middle_name></middle_name>
	<last_name>Chahardouli</last_name>
	<suffix></suffix>
	<first_name_fa></first_name_fa>
	<middle_name_fa></middle_name_fa>
	<last_name_fa></last_name_fa>
	<suffix_fa></suffix_fa>
	<email></email>
	<code></code>
	<orcid></orcid>
	<coreauthor>No</coreauthor>
	<affiliation></affiliation>
	<affiliation_fa></affiliation_fa>
	 </author>


	<author>
	<first_name>S</first_name>
	<middle_name></middle_name>
	<last_name>Abbasian</last_name>
	<suffix></suffix>
	<first_name_fa></first_name_fa>
	<middle_name_fa></middle_name_fa>
	<last_name_fa></last_name_fa>
	<suffix_fa></suffix_fa>
	<email></email>
	<code></code>
	<orcid></orcid>
	<coreauthor>No</coreauthor>
	<affiliation></affiliation>
	<affiliation_fa></affiliation_fa>
	 </author>


	<author>
	<first_name>S</first_name>
	<middle_name></middle_name>
	<last_name>Rostami</last_name>
	<suffix></suffix>
	<first_name_fa></first_name_fa>
	<middle_name_fa></middle_name_fa>
	<last_name_fa></last_name_fa>
	<suffix_fa></suffix_fa>
	<email></email>
	<code></code>
	<orcid></orcid>
	<coreauthor>Yes
</coreauthor>
	<affiliation></affiliation>
	<affiliation_fa></affiliation_fa>
	 </author>


</author_list>


	</article>
</articleset>
</journal>
